Who is sponsoring NCT07379424?

NCT07379424 is sponsored by chen chao Professor.

What drugs are being tested in NCT07379424?

Interventions in NCT07379424: Adjuvant therapy: sintilimab combined with radiotherapy.

What condition does NCT07379424 study?

NCT07379424 studies Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma.

Is NCT07379424 still recruiting?

NCT07379424 is currently not yet recruiting. Last updated 30 January 2026.

Last reviewed 2026-01-30 · How we verify

NCT07379424

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruiting Phase 2 Last updated 30 January 2026

What this trial tests

Phase 2 trial testing Adjuvant therapy: sintilimab combined with radiotherapy in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma in 37 participants. Not yet recruiting.

Timeline

28 January 2026

Primary endpoint
25 August 2027

25 August 2028

Quick facts

Lead sponsor	chen chao Professor
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	28 January 2026
Primary completion	25 August 2027
Estimated completion	25 August 2028
Sites	1 location across China

Drugs / interventions tested

Adjuvant therapy: sintilimab combined with radiotherapy

Conditions studied

Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma — all drugs for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma →

Sponsor

chen chao Professor

Who can join

18 and older, any sex, with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, multi-center Phase II clinical trial. As depicted in the following study design diagram, its objective is to observe and assess the efficacy and safety of sintilimab during the perioperative period in patients with resectable locally advanced head and neck squamous cell carcinoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07379424 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by chen chao Professor
Last refreshed: 30 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07379424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing